IMCR Immunocore Holdings plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMCR

Price (delayed)

$31.54

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.36

Enterprise value

$1.57B

?
Relative Growth: Rel. Growth: 66
Relative Strength: Rel. Strength: 47
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 45
Highlights
IMCR's net income is up by 34% QoQ and by 11% YoY
The EPS has grown by 33% since the previous quarter and by 10% year-on-year
Immunocore Holdings's quick ratio has decreased by 26% YoY but it has increased by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.immunocore.com
Peers: OPK ORGO

Key stats

What are the main financial stats of IMCR

IMCR stock price

How has the Immunocore Holdings stock price performed over time
Intraday
-2.71%
1 week
-0.16%
1 month
-14.48%
1 year
-8.37%
YTD
-9.13%
QTD
-0.66%

Financial performance

How have Immunocore Holdings's revenue and profit performed over time
Revenue
$430.78M
Gross profit
$426.04M
Operating income
-$22.58M
Net income
-$18.07M
Gross margin
98.9%
Net margin
-4.2%
The operating margin has soared by 60% YoY and by 37% QoQ
IMCR's operating income has surged by 51% year-on-year and by 34% since the previous quarter
The net margin has grown by 37% from the previous quarter and by 26% YoY
IMCR's net income is up by 34% QoQ and by 11% YoY

Price vs fundamentals

How does IMCR's price correlate with its fundamentals

Growth

What is Immunocore Holdings's growth rate over time

Valuation

What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
3.82
P/S
3.73
EV/EBIT
166.12
EV/EBITDA
101.22
EV/Sales
3.65
The EPS has grown by 33% since the previous quarter and by 10% year-on-year
IMCR's price to book (P/B) is 35% less than its 5-year quarterly average of 6.0 and 6% less than its last 4 quarters average of 4.2
The equity rose by 8% year-on-year and by 7% since the previous quarter
The stock's price to sales (P/S) is 71% less than its 5-year quarterly average of 13.2 and 9% less than its last 4 quarters average of 4.2
The revenue is up by 21% year-on-year and by 4.4% since the previous quarter

Efficiency

How efficient is Immunocore Holdings business performance
The ROE is up by 37% since the previous quarter and by 17% year-on-year
The return on assets has increased by 32% since the previous quarter and by 11% year-on-year

Dividends

What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMCR.

Financial health

How did Immunocore Holdings financials performed over time
The total assets is 60% greater than the total liabilities
Immunocore Holdings's quick ratio has decreased by 26% YoY but it has increased by 8% from the previous quarter
The current ratio fell by 24% YoY but it rose by 7% QoQ
The debt is 3.6% more than the equity
The equity rose by 8% year-on-year and by 7% since the previous quarter
The debt to equity is down by 7% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.